Project Grant R00HL157549

Award Date 4/19/24
Completion Date 3/31/27
Dollars Obligated $996K
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
New Orleans, LA 70118, USA
Similar Awards
This Project Grant award from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), provides $493,409 to Oregon Health & Science University (OHSU) to investigate the role of the renin-angiotensin system (RAS) at the maternal-fetal interface. The key objectives are to determine the cell-specific contributions of the ACE2 protein in the placenta and decidua, and to elucidate the function...
This $148,880 Project Grant award from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) supports research on the role of B cells and autoantibodies in preeclampsia and their long-term effects on the offspring. The research aims to: Test the hypothesis that B cells from women with preeclampsia produce autoantibodies that cause hypertension, cerebrovascular dysfunction, and cognitive...
This Project Grant award from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), will provide $456,251 to Colorado State University from August 1, 2024 to May 31, 2029 to conduct research on the mechanisms linking maternal obesity and inflammation to abnormal placental development and preeclampsia. The overarching goal is to test the hypothesis that pro-inflammatory mediators produced by...
This Project Grant award of $1,829,617 from the National Institute of Child Health and Human Development (NICHD) under CFDA 93.865 Child Health and Human Development Extramural Research, aims to develop stem cell-based models to study placental defects associated with early-onset preeclampsia. The 5-year project, commencing on July 1, 2024, will pursue three key objectives: 1) Identify optimal stem cell methods to model abnormal trophoblast differentiation in preeclampsia placentas, 2)...
This Project Grant award for $262,808 from the National Institute of Child Health and Human Development (CFDA 93.865 - Child Health and Human Development Extramural Research) supports research conducted by Beth Israel Deaconess Medical Center, Inc. (Bidmc) to develop and evaluate water-soluble prodrugs of the compound AKT-1005 as a potential treatment for preeclampsia. The key objectives are to synthesize, screen, and test the prodrugs for improved solubility, stability, and release of...
This Project Grant award of $191,965.00 from the National Institute of Child Health and Human Development (CFDA 93.865 - Child Health and Human Development Extramural Research) aims to elucidate the upstream transcription factors controlling preeclampsia-specific gene expression using human trophoblast stem cells as a model system. The key objectives are to 1) identify and functionally validate putative preeclampsia-driver transcription factors that can induce preeclampsia-specific gene...
This Project Grant award from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) provides $485,925 to the University of Massachusetts Boston to develop novel antioxidant compounds for treating preeclampsia, a life-threatening pregnancy complication. The primary goal is to design and synthesize cationic hydrazone antioxidants that can target mitochondria to reduce oxidative stress, improve...
The National Institute of Child Health and Human Development (NICHD) awarded Cedars-Sinai Medical Center a $250,500 Project Grant (CFDA 93.865 - Child Health and Human Development Extramural Research) to conduct research on the role of L-kynurenine deficiency in the pathogenesis of preeclampsia in animal models of impaired renal reserve. The research aims to improve methods for diagnosing and monitoring preeclampsia in high-risk populations, as well as develop targeted, pathophysiology-based...
This federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $127,959 to Colorado State University to conduct research on the impact of maternal obesity and gut dysbiosis on the development of preeclampsia and cardiometabolic disease in offspring. The key products and services to be delivered under this 4-year grant include: 1) Determining if the maternal gut microbiome contributes to pro-...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Program (CFDA 93.837), provides $2,559,308 to Pennsylvania State University to study the impact of severe pre-eclampsia on heart function in women from diverse racial backgrounds. The project aims to (1) characterize the cardiomyopathic genetic profile and potential impact on heart function in women with severe pre-eclampsia across different racial cohorts, and (2)...

NOX2-DERIVED OXIDATIVE STRESS PRODUCED BY T CELLS CONTRIBUTES TO THE DEVELOPMENT OF MATERNAL SYNDROME IN THE DAHL SALT-SENSITIVE RAT. - PROJECT ABSTRACT NOX2-DERIVED OXIDATIVE STRESS PRODUCED BY T CELLS CONTRIBUTES TO THE DEVELOPMENT OF MATERNAL SYNDROME IN THE DAHL SALT-SENSITIVE RAT. PREECLAMPSIA (PE) IS A PREGNANCY-SPECIFIC DISORDER THAT IS CHARACTERIZED BY HYPERTENSION AND PROTEINURIA (MATERNAL SYNDROME) DEVELOPING AFTER THE 20TH WEEK OF GESTATION. PE IS THE LEADING CAUSE OF MATERNAL MORBIDITY AND MORTALITY IN THE UNITED STATES, AFFECTING ABOUT 5-7% OF PREGNANCIES. FURTHERMORE, WOMEN WITH PREEXISTING HYPERTENSION OR CHRONIC KIDNEY DISEASE HAVE AN INCREASED RISK FOR DEVELOPING PE. WITH RATES OF PE RISING IN THE UNITED STATES, THE EXACT MECHANISM(S) RESPONSIBLE FOR THE PATHOGENESIS OF THE DISEASE REMAIN UNDETERMINED. THE CURRENT NOTION OF THE PATHOGENESIS OF PE IS THOUGHT TO BE A TWO-STEP PROCESS: 1) IMPROPER PLACENTATION AND REMODELING OF THE SPIRAL ARTERIES AND 2) DEVELOPMENT OF MATERNAL SYNDROME. CURRENT ANIMAL MODELS REQUIRE EITHER A SURGICAL OR PHARMACOLOGIC INTERVENTION TO DEVELOP PE-LIKE PHENOTYPES; HOWEVER, THESE MODELS ARE NOT CAPABLE OF INVESTIGATING THE FIRST STEP IN THE DISEASE PROCESS. OUR PRELIMINARY DATA DEMONSTRATE THAT THE DAHL SALT-SENSITIVE (SS) RAT IS JUST SUCH AN ANIMAL MODEL TO HELP INVESTIGATE MECHANISMS OF PE SINCE IT SPONTANEOUSLY DEVELOPS PE WHILE REMAINING ON A LOW SALT (0.4% NACL) DIET. THE PRESENT STUDIES WILL TEST THE CENTRAL HYPOTHESIS THAT MATERNAL SYNDROME IN DAHL SS RATS IS AN OUTCOME OF IMPROPER PLACENTATION LEADING TO THE INFILTRATION OF T CELLS INTO KIDNEY AND PLACENTAL TISSUES CAUSING SUBSEQUENT RELEASE OF REACTIVE OXYGEN SPECIES (ROS) THAT CONTRIBUTES TO ENDOTHELIAL DYSFUNCTION AND THE DEVELOPMENT HYPERTENSION AND RENAL DAMAGE. TO TEST THIS HYPOTHESIS, THREE SPECIFIC AIMS ARE PROPOSED. AIM 1 WILL FIRST TEST THE HYPOTHESIS THAT T CELL DERIVED ROS (NOX2-DERIVED) CAUSES MATERNAL SYNDROME IN DAHL SS RATS UTILIZING A NOVEL SPLENOCYTE TRANSFER APPROACH. AIM 2 WILL DEMONSTRATE THAT T-CELL DERIVED ROS RESULTS IN ENDOTHELIAL DYSFUNCTION THAT DEVELOPS IN MATERNAL SYNDROME. INTERESTINGLY, THIS MATERNAL SYNDROME PHENOTYPE OCCURS IN A DIVERGENT FASHION WITH ABOUT 50% OF SS RATS DEVELOPING MATERNAL AND THE OTHER HALF ARE PROTECTED. AIM 3 WILL INVESTIGATE THE RENAL DYSFUNCTION THAT OCCURS DURING PE AND THE INCREASED RISK OF DEVELOPING CHRONIC KIDNEY DISEASE LEADING TO INCREASED MORTALITY IN DAHL SS RATS. THIS MATERNAL SYNDROME PHENOTYPE IS CONSISTENT WITH WHAT IS OBSERVED IN CLINICAL SETTINGS, AND THIS MODEL PROVIDES A UNIQUE OPPORTUNITY TO STUDY THE WHOLE DISEASE PROCESS OF PE. COMPLETION OF THE STUDIES IN THIS PROPOSAL WILL ESTABLISH THE INTERACTION BETWEEN T CELL-DERIVED ROS AND ENDOTHELIAL FUNCTION IN PE TO BETTER UNDERSTAND THE UNDERLYING MECHANISMS OF PE.

Posted 4/19/24, 12:00 AM